Axsome Therapeutics shares rise 1.08% intraday as RBC Capital Markets maintains its stance on the biopharma company.
ByAinvest
Tuesday, Jul 8, 2025 10:41 am ET1min read
AXSM--
Axsome Therapeutics, Inc. rose 1.08% in intraday trading, with RBC Capital Markets maintaining its stance on the biopharma company. Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and providing therapies for central nervous system (CNS) disorders with limited treatment options. The company's commercial products and development programs include Auvelity and Sunosi, which are used for treating severe depressive disorders and excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea, respectively.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet